Literature DB >> 3464023

Measurement by radioimmunoassay of prostaglandins as their methyl oximes.

R W Kelly, S Deam, M J Cameron, R F Seamark.   

Abstract

Antisera have been raised to the following prostaglandins as their methyl oximes; PGE2, PGD2, 13-14-dihydro-15-oxo PGE2, 13,14-dihydro-15-oxo PGF2 alpha, 6-oxo PGF1 alpha, 6-oxo PGE1 and thromboxane B2. These antisera have good specificity and sensitivity and their use allows the immediate treatment of biological fluids with oximating solution which prevents sample decomposition during storage. A methyl oximating reagent is described which gives greater than 95% conversion of PGs to their methyl oximes by treating samples at 20 degrees C overnight. The use of this reagent allows easy and reliable sample derivatisation prior to assay with the above antisera. Since the antisera (with the exception of that for thromboxane B2) do not recognise the underivatised PG or the oxime (=NOH) form, oxime formation can be carried out in parallel with methyl oxime formation and the oximated portion of the sample can act as a "reference" for the methyl oximated portion, which will allow non specific interference to be recognised.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3464023     DOI: 10.1016/0262-1746(86)90201-5

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  13 in total

1.  Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.

Authors:  V A Fadok; D L Bratton; A Konowal; P W Freed; J Y Westcott; P M Henson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

2.  The release of prostaglandin D2 from human skin in vivo and in vitro during immediate allergic reactions.

Authors:  R M Barr; O Koro; D M Francis; A K Black; T Numata; M W Greaves
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

3.  Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.

Authors:  A S Taha; S McLaughlin; P J Holland; R W Kelly; R D Sturrock; R I Russell
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

4.  Immunosuppression by seminal prostaglandins.

Authors:  A J Quayle; R W Kelly; T B Hargreave; K James
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

5.  The effects of some anti-arthritic drugs and cytokines on the shape and function of rodent macrophages.

Authors:  D R Haynes; M W Whitehouse; B Vernon-Roberts
Journal:  Int J Exp Pathol       Date:  1991-02       Impact factor: 1.925

6.  Differential release of prostaglandins by organ cultures of human fetal trachea and lung.

Authors:  R Hume; J Bell; D Cossar; M Giles; A Hallas; R Kelly
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-01       Impact factor: 2.416

7.  Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99.

Authors:  Lora G Bankova; Juying Lai; Eri Yoshimoto; Joshua A Boyce; K Frank Austen; Yoshihide Kanaoka; Nora A Barrett
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-16       Impact factor: 11.205

8.  Is aspirin a prodrug for antioxidant and cytokine-modulating oxymetabolites?

Authors:  D R Haynes; P F Wright; S J Gadd; M W Whitehouse; B Vernon-Roberts
Journal:  Agents Actions       Date:  1993-05

9.  The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin.

Authors:  R M Barr; A K Black; P M Dowd; O Koro; K Mistry; J L Isaacs; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

10.  Peritoneal lavage fluid alters patterns of eicosanoid production in murine bone marrow-derived and peritoneal macrophages: dependency on inflammatory state of the peritoneum.

Authors:  S E Wenzel; J B Trudeau; D W Riches; J Y Westcott; P M Henson
Journal:  Inflammation       Date:  1993-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.